{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T15:11:34Z","timestamp":1778685094740,"version":"3.51.4"},"reference-count":33,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"unspecified","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100011110","name":"UCB","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011110","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2026,4,2]]},"published-print":{"date-parts":[[2026,4]]},"abstract":"\n Objective<\/jats:title>\n To assess the sustained, long-term efficacy of bimekizumab in improving patient symptoms and health-related quality of life (HRQoL) in axial spondyloarthritis (axSpA) to 3 years.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Both BE MOBILE 1 (non-radiographic axSpA) and 2 (radiographic axSpA) comprised a 16-week double-blind, placebo-controlled treatment period and a 36-week maintenance period. From week 16, all patients received subcutaneous bimekizumab 160\u2009mg every 4\u2009weeks. At week 52, eligible patients could enter the open-label extension (OLE), BE MOVING and continue bimekizumab treatment. Here, we report pooled results for changes in spinal pain, morning stiffness (mean of Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Q5 and Q6), physical function (Bath Ankylosing Spondylitis Functional Index (BASFI)), fatigue (BASDAI Q1 and Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue), sleep quality (Medical Outcomes Study Sleep (MOS-Sleep-R) Index II) and HRQoL (36-Item Short Form Questionnaire (SF-36) Physical Component Summary (PCS)\/Mental Component Summary; Ankylosing Spondylitis Quality of Life (ASQoL)) to 3 years in the overall study population; for spinal pain and physical function, patient-level data are also reported.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of the 494\/586 (84.3%) randomised patients who entered the OLE, 425\/494 (86.0%) completed week 164. At week 164, patients reported mean improvements from baseline in total (\u20134.3) and nocturnal (\u20134.3) spinal pain, morning stiffness (\u20134.3), physical function (BASFI: \u20132.9), fatigue (BASDAI Q1: \u20133.5, FACIT-Fatigue: +9.7), sleep (MOS-Sleep-R Index II: +10.8) and HRQoL (SF-36 PCS: +12.3; ASQoL: \u20135.6). Rapid and sustained patient-level improvements to week 164 in spinal pain and physical function levels were observed.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Bimekizumab treatment led to rapid and sustained improvements in key patient symptoms and HRQoL to 3 years, emphasising its long-term value in controlling symptoms which profoundly affect patients\u2019 experience and daily lives.<\/jats:p>\n <\/jats:sec>\n \n Trial registration numbers<\/jats:title>\n \n BE MOBILE 1 (\n NCT03928704<\/jats:ext-link>\n ), BE MOBILE 2 (\n NCT03928743<\/jats:ext-link>\n ) and BE MOVING (\n NCT04436640<\/jats:ext-link>\n ).\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/rmdopen-2025-006670","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:26:27Z","timestamp":1778682387000},"page":"e006670","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Bimekizumab treatment for sustained improvements in patient symptoms and health-related quality of life to 3 years in axial spondyloarthritis: results from the BE MOBILE studies and their open-label extension"],"prefix":"10.1136","volume":"12","clinical-trial-number":[{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928743","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04436640","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928743","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04436640","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928704","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03928743","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct04436640","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4527-852X","authenticated-orcid":false,"given":"Victoria","family":"Navarro-Comp\u00e1n","sequence":"first","affiliation":[{"name":"Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5668-4497","authenticated-orcid":false,"given":"Uta","family":"Kiltz","sequence":"additional","affiliation":[{"name":"Ruhr University Bochum, Bochum, Germany"},{"name":"Rheumazentrum Ruhrgebiet, Herne, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J","family":"Mease","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, Washington, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen","family":"Dubreuil","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Boston University School of Medicine, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7863-9176","authenticated-orcid":false,"given":"Karl","family":"Gaffney","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Norfolk and Norwich University Hospital NHS Trust, Norfolk, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atul","family":"Deodhar","sequence":"additional","affiliation":[{"name":"Division of Arthritis and Rheumatic Diseases, Oregon Health & Science University, Portland, Oregon, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christine","family":"de la Loge","sequence":"additional","affiliation":[{"name":"UCB, Brussels, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chetan","family":"Prajapati","sequence":"additional","affiliation":[{"name":"UCB, Slough, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Kavanagh","sequence":"additional","affiliation":[{"name":"UCB, Morrisville, North Carolina, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9683-3407","authenticated-orcid":false,"given":"Helena","family":"Marzo-Ortega","sequence":"additional","affiliation":[{"name":"NIHR Leeds Biomedical Research Centre, The Leeds Teaching Hospitals NHS Trust and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"key":"2026051307253325000_12.2.e006670.1","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0140-6736(24)02263-3","article-title":"Axial spondyloarthritis","volume":"405","author":"Navarro-Comp\u00e1n","year":"2025","journal-title":"Lancet"},{"key":"2026051307253325000_12.2.e006670.2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab544"},{"key":"2026051307253325000_12.2.e006670.3","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.210206"},{"key":"2026051307253325000_12.2.e006670.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2021.07.021"},{"key":"2026051307253325000_12.2.e006670.5","unstructured":"Baraliakos X , Navarro-Comp\u00e1n V , Nikiphorou E , et al . Current disease management and treatment satisfaction in axial spondyloarthritis (axspa) in europe: patient and rheumatologist perspectives [abstract]. Arthritis Rheumatol; 2024"},{"key":"2026051307253325000_12.2.e006670.6","doi-asserted-by":"publisher","DOI":"10.1097\/RHU.0000000000001544"},{"key":"2026051307253325000_12.2.e006670.7","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.150463"},{"key":"2026051307253325000_12.2.e006670.8","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1093\/rheumatology\/keaf009","article-title":"Long-term safety and efficacy of bimekizumab in axial spondyloarthritis: 2-year results from two phase 3 studies","volume":"64","author":"Baraliakos","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026051307253325000_12.2.e006670.9","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2025-006013","article-title":"Sustained improvements in spinal pain, morning stiffness, fatigue, sleep, physical function and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: 2-year results from two phase 3 studies","volume":"11","author":"Marzo-Ortega","year":"2025","journal-title":"RMD Open"},{"key":"2026051307253325000_12.2.e006670.10","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004202","article-title":"Improved physical functioning, sleep, work productivity and overall health-related quality of life with bimekizumab in patients with axial spondyloarthritis: results from two phase 3 studies","volume":"10","author":"Dubreuil","year":"2024","journal-title":"RMD Open"},{"key":"2026051307253325000_12.2.e006670.11","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2024-0223"},{"key":"2026051307253325000_12.2.e006670.12","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-005081","article-title":"Long-term safety and sustained efficacy of bimekizumab in patients with ankylosing spondylitis (radiographic axial spondyloarthritis): 5-year results from BE AGILE (phase 2b) and its open-label extension","volume":"11","author":"Deodhar","year":"2025","journal-title":"RMD Open"},{"key":"2026051307253325000_12.2.e006670.13","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2023-224803"},{"key":"2026051307253325000_12.2.e006670.14","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-223595"},{"key":"2026051307253325000_12.2.e006670.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222747"},{"key":"2026051307253325000_12.2.e006670.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2007.09.005"},{"key":"2026051307253325000_12.2.e006670.17","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J Rheumatol"},{"key":"2026051307253325000_12.2.e006670.18","first-page":"2281","article-title":"A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index","volume":"21","author":"Calin","year":"1994","journal-title":"J Rheumatol"},{"key":"2026051307253325000_12.2.e006670.19","doi-asserted-by":"crossref","DOI":"10.1186\/s41687-024-00769-x","article-title":"The Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) scale in patients with axial spondyloarthritis: psychometric properties and clinically meaningful thresholds for interpretation","volume":"8","author":"Cella","year":"2024","journal-title":"J Patient Rep Outcomes"},{"key":"2026051307253325000_12.2.e006670.20","unstructured":"de la Loge C , Fofana F , Voiniciuc D , et al . Psychometric properties and thresholds to guide interpretations of Bath Ankylosing Spondylitis Disease Activity Index Fatigue Question 1 (BASDAI-Q1) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue) subscale in axial spondyloarthritis (axSpA). ICS Ghent; 2024"},{"key":"2026051307253325000_12.2.e006670.21","doi-asserted-by":"publisher","DOI":"10.1016\/S0885-3924(96)00274-6"},{"key":"2026051307253325000_12.2.e006670.22","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1002\/art.39805","article-title":"Effect of Secukinumab on Patient-Reported Outcomes in Patients With Active Ankylosing Spondylitis: A Phase III Randomized Trial (MEASURE 1)","volume":"68","author":"Deodhar","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2026051307253325000_12.2.e006670.23","doi-asserted-by":"crossref","DOI":"10.1186\/s41687-021-00311-3","article-title":"The development and validation of a revised version of the Medical Outcomes Study Sleep Scale (MOS Sleep-R)","volume":"5","author":"Yarlas","year":"2021","journal-title":"J Patient Rep Outcomes"},{"key":"2026051307253325000_12.2.e006670.24","unstructured":"Maruish ME . User\u2019s guide for the MOS Sleep Scale\u2013Revised. Lincoln, RI: QualityMetric Incorporated, 2012."},{"key":"2026051307253325000_12.2.e006670.25","unstructured":"Maruish ME . User\u2019s Manual for the SF-36v2 Health Survey. 3rd edn. Lincoln, RI: QualityMetric Incorporated, 2011."},{"key":"2026051307253325000_12.2.e006670.26","doi-asserted-by":"publisher","DOI":"10.1136\/ard.62.1.20"},{"key":"2026051307253325000_12.2.e006670.27","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s11136-020-02686-0","article-title":"Validation of the Ankylosing Spondylitis Quality of Life assessment tool in patients with non-radiographic axial spondyloarthritis","volume":"30","author":"Hoepken","year":"2021","journal-title":"Qual Life Res"},{"key":"2026051307253325000_12.2.e006670.28","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/annrheumdis-2024-eular.2107","article-title":"POS0506\u2005The longitudinal association between disease activity, function and health-related quality of life in axial spondyloarthritis: results from the desir cohort","volume":"83","author":"Ortolan","year":"2024","journal-title":"Ann Rheum Dis"},{"key":"2026051307253325000_12.2.e006670.29","doi-asserted-by":"crossref","first-page":"152571","DOI":"10.1016\/j.semarthrit.2024.152571","article-title":"Improvement in spinal pain at night and its impact on long-term outcomes in radiographic axial spondyloarthritis: Results from Ixekizumab COAST-V randomised trial","volume":"69","author":"Ramiro","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"2026051307253325000_12.2.e006670.30","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1080\/03009742.2023.2281069","article-title":"Reduced sleep quality is highly prevalent and associated with physical function and cardiorespiratory fitness in patients with axial spondyloarthritis: a cross-sectional study","volume":"53","author":"Fongen","year":"2024","journal-title":"Scand J Rheumatol"},{"key":"2026051307253325000_12.2.e006670.31","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1007\/s40744-023-00550-4","article-title":"Effect of Upadacitinib on Quality of Life and Work Productivity in Active Non-radiographic Axial Spondyloarthritis: Results From Randomized Phase 3 Trial SELECT-AXIS 2","volume":"10","author":"Kiltz","year":"2023","journal-title":"Rheumatol Ther"},{"key":"2026051307253325000_12.2.e006670.32","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-002165","article-title":"Efficacy and safety of ixekizumab treatment in patients with axial spondyloarthritis: 2-year results from COAST","volume":"8","author":"Braun","year":"2022","journal-title":"RMD Open"},{"key":"2026051307253325000_12.2.e006670.33","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1136\/annrheumdis-2022-eular.169","article-title":"POS0931\u2005Efficacy and improvement in patient-reported outcomes at weeks 16 and 52 in ixekizumab treated biological na\u00efve patients with radiographic axial spondyloarthritis achieving clinically important pain at night reduction at week 16: results from coast-V trial","volume":"81","author":"Ramiro","year":"2022","journal-title":"Ann Rheum Dis"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-006670","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T14:26:33Z","timestamp":1778682393000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-006670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,5,13]]},"published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1136\/rmdopen-2025-006670"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-006670","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4]]}}}